Acromegaly - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 73 pages report, published by Global Markets Direct

Keywords : Acromegaly Therapeutic Products under Development, Key Players in Acromegaly Therapeutics, Acromegaly Pipeline Overview, Acromegaly Pipeline, Acromegaly Pipeline Assessment

Report ThumbnailSeptember-2013
Acromegaly - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Acromegaly - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Acromegaly, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acromegaly. Acromegaly - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acromegaly.
- A review of the Acromegaly products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acromegaly pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Acromegaly.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Acromegaly, H2 2013 8
  • Products under Development for Acromegaly - Comparative Analysis, H2 2013 9
  • Products under Development by Companies, H2 2013 10
  • Late Stage Products, H2 2013 12
  • Mid Clinical Stage Products, H2 2013 13
  • Discovery and Pre-Clinical Stage Products, H2 2013 14
  • Assessment by Monotherapy Products, H2 2013 28
  • Assessment by Route of Administration, H2 2013 29
  • Assessment by Stage and Route of Administration, H2 2013 30
  • Assessment by Molecule Type, H2 2013 31
  • Assessment by Stage and Molecule Type, H2 2013 32
  • List of Tables
  • Number of Products Under Development for Acromegaly, H2 2013 8
  • Products under Development for Acromegaly - Comparative Analysis, H2 2013 9
  • Number of Products under Development by Companies, H2 2013 11
  • Comparative Analysis by Late Stage Development, H2 2013 12
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 14
  • Products under Development by Companies, H2 2013 15
  • Merck & Co., Inc., H2 2013 16
  • Novartis AG, H2 2013 17
  • Antisense Therapeutics Limited, H2 2013 18
  • Paladin Labs Inc., H2 2013 19
  • Asterion Ltd, H2 2013 20
  • Camurus AB, H2 2013 21
  • Syntaxin Ltd, H2 2013 22
  • GP Pharm, S.A., H2 2013 23
  • Aegis Therapeutics, LLC, H2 2013 24
  • Peptron, Inc., H2 2013 25
  • Q Chip Ltd., H2 2013 26
  • Crinetics Pharmaceuticals, Inc., H2 2013 27
  • Assessment by Monotherapy Products, H2 2013 28
  • Assessment by Stage and Route of Administration, H2 2013 30
  • Assessment by Stage and Molecule Type, H2 2013 32
  • Acromegaly Therapeutics - Drug Profile Updates 54
  • Acromegaly Therapeutics - Discontinued Products 61
  • Acromegaly Therapeutics - Dormant Products 62
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Acromegaly Overview 7
  • Therapeutics Development 8
  • An Overview of Pipeline Products for Acromegaly 8
  • Acromegaly Therapeutics under Development by Companies 10
  • Late Stage Products 12
  • Comparative Analysis 12
  • Mid Clinical Stage Products 13
  • Comparative Analysis 13
  • Discovery and Pre-Clinical Stage Products 14
  • Comparative Analysis 14
  • Acromegaly Therapeutics - Products under Development by Companies 15
  • Companies Involved in Acromegaly Therapeutics Development 16
  • Merck & Co., Inc. 16
  • Novartis AG 17
  • Antisense Therapeutics Limited 18
  • Paladin Labs Inc. 19
  • Asterion Ltd 20
  • Camurus AB 21
  • Syntaxin Ltd 22
  • GP Pharm, S.A. 23
  • Aegis Therapeutics, LLC 24
  • Peptron, Inc. 25
  • Q Chip Ltd. 26
  • Crinetics Pharmaceuticals, Inc. 27
  • Acromegaly - Therapeutics Assessment 28
  • Assessment by Monotherapy Products 28
  • Assessment by Route of Administration 29
  • Assessment by Molecule Type 31
  • Drug Profiles 33
  • ATL-1103 - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • SXN-101959 - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • DG-3173 - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • octreotide acetate - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • octreotide acetate - Drug Profile 39
  • Product Description 39
  • Mechanism of Action 39
  • R&D Progress 39
  • GH Antagonists - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • octreotide acetate - Drug Profile 41
  • Product Description 41
  • Mechanism of Action 41
  • R&D Progress 41
  • octreotide acetate LAR - Drug Profile 43
  • Product Description 43
  • Mechanism of Action 43
  • R&D Progress 43
  • FP-002 - Drug Profile 44
  • Product Description 44
  • Mechanism of Action 44
  • R&D Progress 44
  • L-054522 - Drug Profile 45
  • Product Description 45
  • Mechanism of Action 45
  • R&D Progress 45
  • pasireotide LAR - Drug Profile 46
  • Product Description 46
  • Mechanism of Action 46
  • R&D Progress 46
  • pasireotide LAR - Drug Profile 48
  • Product Description 48
  • Mechanism of Action 48
  • R&D Progress 48
  • Somatostatin Agonists - Drug Profile 50
  • Product Description 50
  • Mechanism of Action 50
  • R&D Progress 50
  • octreotide SR - Drug Profile 51
  • Product Description 51
  • Mechanism of Action 51
  • R&D Progress 51
  • octreotide - Drug Profile 52
  • Product Description 52
  • Mechanism of Action 52
  • R&D Progress 52
  • Acromegaly Therapeutics - Drug Profile Updates 54
  • Acromegaly Therapeutics - Discontinued Products 61
  • Acromegaly Therapeutics - Dormant Products 62
  • Acromegaly - Product Development Milestones 63
  • Featured News & Press Releases 63
  • Aug 02, 2013: Antisense Therapeutics Provides ATL1103 Phase II Trial Update 63
  • Jun 17, 2013: Ipsen Announces Clinically Relevant Results In Phase III PRIMARYS Study With Somatuline Autogel In Acromegaly Patients 64
  • Jun 14, 2013: Antisense Therapeutics Reports Positive New Animal Data On ATL1103 For Treatment Of Acromegaly 65
  • Apr 10, 2013: Antisense Therapeutics Commences Dosing Of Patients For Phase II Clinical Trial Of ATL1103 In Acromegaly 66
  • Apr 03, 2013: Aspireo Pharma Reports Somatoprim Phase IIa Proof Of Concept Results In Acromegaly 67
  • Mar 22, 2013: Antisense Therapeutics Announces Presentation Of Phase I Study Data On ATL1103 At Acromegaly Conference 67
  • Jan 25, 2013: Antisense Therapeutics Initiates Phase II Clinical Trial Of ATL1103 In Acromegaly 68
  • Jan 17, 2013: Teijin Pharma Launches Ipsen's Somatuline Subcutaneous Injection For Treatment Of Acromegaly And Pituitary Gigantism In Japan 69
  • Jan 07, 2013: Aspireo Pharma Reports Phase Ib Interim Data For Somatoprim 70
  • Nov 26, 2012: Aspireo Pharma Announces EMA's Committee For Orphan Medicinal Products Recommends Orphan Medicinal Product Designation For Somatoprim 70
  • Appendix 72
  • Methodology 72
  • Coverage 72
  • Secondary Research 72
  • Primary Research 72
  • Expert Panel Validation 72
  • Contact Us 73
  • Disclaimer 73

Please select a license type

Share

Related Products

Global Markets DirectAcromegaly - Pipeline Review, H2 2013Product ThumbnailAcromegaly - Pipeline Review, H2 2013, Industry ReportProduct #: 113304
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved